- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
RSNA 2021 Preview: Canon Medical Touts Advances Across Modalities
Learn more about what Canon Medical will be showcasing virtually at RSNA 2021.
RSNA 2021 is quickly approaching as members of the greater radiology healthcare community prepare to immerse themselves in five days of scientific sessions, key lectures, and exciting product demonstrations.
Diagnostic Imaging sat down with Canon Medical's David Hashimoto, Senior Director, Full Line BUs and Solutions Marketing, to learn more about what Canon has planned for their virtual participation in RSNA 2021.
Canon Medical will offer attendees--both in-person and virtual--an immersive experience that includes live product demonstrations and scheduled briefings with Canon Medical experts across the breadth of their portfolio, including CT, molecular imaging, MRI, ultrasound, X-ray, interventional radiology, and healthcare IT.
For the latest coverage of RSNA 2021, click here.
In addition, Canon Medical will also be hosting a roundtable discussion, "State of AI in Radiology Today," featuring a distinguished panel of speakers who will discuss the financial, technical, clinical, and regulatory considerations of applying AI in today's radiology practice and in the future.
Those interested in the roundtable discussion can pre-register here.
To learn more about what Canon Medical will be sharing at RSNA 2021, click here.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Can AI Facilitate Single-Phase CT Acquisition for COPD Diagnosis and Staging?
December 12th 2024The authors of a new study found that deep learning assessment of single-phase CT scans provides comparable within-one stage accuracies to multiphase CT for detecting and staging chronic obstructive pulmonary disease (COPD).
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
